1. Home
  2. GRNT vs CBIO Comparison

GRNT vs CBIO Comparison

Compare GRNT & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Granite Ridge Resources Inc.

GRNT

Granite Ridge Resources Inc.

HOLD

Current Price

$4.83

Market Cap

662.8M

Sector

Finance

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$20.45

Market Cap

557.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRNT
CBIO
Founded
2013
2003
Country
United States
United States
Employees
N/A
44
Industry
Blank Checks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
662.8M
557.8M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
GRNT
CBIO
Price
$4.83
$20.45
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$6.00
$26.67
AVG Volume (30 Days)
893.1K
293.9K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
7.36%
N/A
EPS Growth
28.57
N/A
EPS
N/A
N/A
Revenue
$450,306,000.00
N/A
Revenue This Year
$18.12
N/A
Revenue Next Year
$13.12
$279.20
P/E Ratio
N/A
N/A
Revenue Growth
18.49
N/A
52 Week Low
$4.18
$8.72
52 Week High
$6.59
$27.41

Technical Indicators

Market Signals
Indicator
GRNT
CBIO
Relative Strength Index (RSI) 35.11 52.46
Support Level $4.18 $10.83
Resistance Level $5.45 $21.14
Average True Range (ATR) 0.22 2.10
MACD -0.08 0.11
Stochastic Oscillator 9.96 58.83

Price Performance

Historical Comparison
GRNT
CBIO

About GRNT Granite Ridge Resources Inc.

Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: